Dr. Mikhail N. Kosiborod, (Mick-hale Kosee-bore-od) Cardiologist at Saint Luke’s Mid America Heart Institute and Vice President of Research at Saint Luke’s Health System, discuses the issue of heart failure, define it, demystify it and share information about possible treatment options and latest advancements surrounding the condition.
MORE THAN EIGHT MILLION PEOPLE ARE ESTIMATED TO HAVE “IT” BY 2030. “IT,” IS HEART FAILURE.
NOW MORE THAN EVER, IN LIGHT OF COVID-19, PEOPLE ARE FOCUSING ON THEIR HEALTH AND HOW TO TAKE BETTER CARE OF THEMSELVES, ESPECIALLY THOSE WITH UNDERLYING CONDITIONS THAT MAKES THEM MORE VULNERABLE TO THE VIRUS.
HERE TO HELP US UNDERSTAND WHAT HEART FAILURE IS, WHO’S AT RISK AND WHAT TO DO ABOUT IT, IS DR. KOSIBOROD.
Mikhail Kosiborod, MD, FACC, FAHA – Kansas City, MO, USA
Dr. Mikhail Kosiborod is a cardiologist, the Vice President of Research at Saint Luke’s Health System, Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, and Professor of Medicine at the University of Missouri-Kansas City. Dr. Kosiborod received training in clinical research, epidemiology and health policy through the Robert Wood Johnson Clinical Scholars Program, as well as clinical training in cardiovascular medicine at Yale University School of Medicine. Dr. Kosiborod is an internationally recognized expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, as well as quality of care and outcomes. Dr. Kosiborod has authored and co-authored over 220 peer-reviewed publications, including scientific statements and position documents. Dr. Kosiborod is involved in the leadership of multiple clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multicenter trials in diabetes and cardiovascular disease.